ReviewExpert opinion on drug delivery2021
Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery.
Review in Expert opinion on drug delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 256 citations in OpenAlex.
- CRISPR/Cas9-based nanodelivery systems for precision gene editing in neuroinflammation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Nano-antimicrobial peptides (Nano-AMPs) to combat resistant gram-negative bacteria.Drug delivery and translational research · 2026Review
- Engineering Advanced Nanomedicine Against Depression: From Treatment Challenges to Delivery Strategies.Advanced healthcare materials · 2026Review
- Wound Healing Potential of Multifunctional Nanomaterials: Mechanism, Future Prospects, and Challenges.Pharmaceutics · 2026Review
- Linker Design in Antibody-Drug Conjugates: Balancing Stability and Drug Release.Pharmaceutics · 2026Review
- Nanomedicine targeting neuroinflammatory pathways in Alzheimer's disease: a new frontier in inflammopharmacology.Inflammopharmacology · 2026Review
- Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies.Molecular cancer · 2026Review
- Marine-Derived Nanocarriers for Immunomodulatory Drug Delivery: a Review On Convergence of Marine Pharmacology and Nanotechnology.Applied biochemistry and biotechnology · 2026Review
- Phytochemicals in Alzheimer's Disease Prevention and Management: Molecular Mechanisms, Therapeutic Potential, Translational Challenges, and Emerging Research Directions.International journal of molecular sciences · 2026Review
- Degradable MMP9-responsive high-density lipoprotein nanoparticles enable efficient siRNA-PGRN and quercetin delivery to remodel the fibrotic microenvironment and attenuate renal fibrosis.Journal of nanobiotechnology · 2026Article
- Mechanically Triggered DNA Nanovehicles for Targeted Dual-Drug Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Navigating toxicity in lung cancer immunotherapy: challenges and advances in Nano medicine drug delivery.Journal of the Egyptian National Cancer Institute · 2026Review
- Cytotoxicity and immunogenic cell death studies of water-soluble tetrahedral Ga(iii) or Fe(iii) coordination cages containing a Au(i) anticancer drug as guest.Inorganic chemistry frontiers · 2026Article
- Ginsenosides as epigenetic modulators: HDAC, DNMT, and miRNA-targeted mechanisms in tumour suppression.Molecular biology reports · 2026Review
- Artificial intelligence-assisted design and optimization of stimuli-responsive nanocarriers for smart drug delivery.Materials today. Bio · 2026Review
- Emerging Role of Nanostructured Lipid Carriers in Overcoming Cancer Treatment Challenges.Pharmaceutical research · 2026Review
- Kaempferol-based nanocarriers as a potential therapeutic strategy against drug-resistant lung cancer.Cancer cell international · 2026Review
- Coordination chemistry-enabled drug delivery systems: metal-ligand platforms for controlled release and targeted therapeutics.Journal of nanobiotechnology · 2026Review
- Poor prognosis outcome tumors, bacteria-infected tumors and nanodrugs: current evidence and hypotheses towards a paradigm change for treatment.Cancer biology & medicine · 2026Review
- The Role and Potential of Nanotechnology in Improving Solubility and Enhancing Bioavailability.Pharmaceutics · 2026Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
introductionNanocarrier-based delivery systems offer multiple benefits to overcome limitations of the traditional drug dosage forms, such as protection of the drug, enhanced bioavailability, targeted delivery to disease site, etc. Nanocarriers have exhibited tremendous successes in targeted delivery of therapeutics to the desired tissues and cells with improved bioavailability, high drug loading capacity, enhanced intracellular delivery, and better therapeutic effect. A specific design of stimuli-responsive nanocarriers allows for changing their structural and physicochemical properties in response to exogenous and endogenous stimuli. These nanocarriers show a promise in site specific controlled release of therapeutics under certain physiological conditions or external stimuli. AREAS COVERED: This review highlights recent progresses on the multifunctional and stimuli-sensitive nanocarriers for targeted therapeutic drug delivery applications. EXPERT OPINION: The progress from single functional to multifunctional nanocarriers has shown tremendous potential for targeted delivery of therapeutics. On our opinion, the future of targeted delivery of drugs, nucleic acids, and other substances belongs to the site-targeted multifunctional and stimuli-based nanoparticles with controlled release. Targeting of nanocarriers to the disease site enhance the efficacy of the treatment by delivering more therapeutics specifically to the affected cells and substantially limiting adverse side effects upon healthy organs, tissues, and cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.